So Nagai
Sapporo, 0600061, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
Pemafibrate Improves Lipid and Liver Metabolism in Adult GH Deficiency: A Prospective Observational Study.
Journal: Journal of the Endocrine Society
Published: July 02, 2025
Effect of pemafibrate on high-density lipoprotein cholesterol levels and subspecies in a patient with cholesteryl ester transfer protein deficiency: A case report with mechanistic insights.
Journal: Journal of clinical lipidology
Published: June 12, 2025
Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: A multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
Journal: Diabetes, obesity & metabolism
Published: October 01, 2024
Positive association between proinsulin and fatty liver index in people with type 2 diabetes.
Journal: Endocrine journal
Published: December 20, 2023
Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease.
Journal: Diabetes & metabolism journal
Published: October 15, 2023
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
Journal: Diabetes, obesity & metabolism
Published: October 13, 2023
Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage.
Journal: Diabetology & metabolic syndrome
Published: July 23, 2023
Inverse association between glucose variability and body fat in type 2 diabetes with impaired endogenous insulin secretion assessed using continuous glucose monitoring: A prospective observational study.
Journal: Diabetes, obesity & metabolism
Published: December 16, 2022
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Journal: Diabetes, obesity & metabolism
Published: November 25, 2022
Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study.
Journal: Diabetes research and clinical practice
Published: July 29, 2022
Last Updated: 09/26/2026